Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix

International Journal of Gynecological Pathology

Volumn 23, Issue 1, 2004, Pages 13-17

  Rosty, Christophe ^a   Couturier, Jérôme ^a   Vincent Salomon, Anne ^a   Genin, Pascal ^a   Fréneaux, Paul ^a   Sigal Zafrani, Brigitte ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Cervical carcinoma; Fluorescent in situ hybridization; HER 2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PROTEIN P185;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CANCER INVASION; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 0347511895     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000092137.88121.8d     Document Type: Article

References (35)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Couturier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000;13:1238-43.
3. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999;18:138-43.
4. Meden H, Marx D, Roegglen T, et al. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998;17:61-5.
5. D'Emilia J, Bulovas K, D'Ercole K, et al. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989;4:1233-9.
6. Mizutani T, Onda M, Tokunaga A, et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8.
7. Kern JA, Schwartz DA. Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
8. Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. Anticancer Res 2000;20:2091-6.
9. Miyamoto H, Kubota Y, Noguchi S, et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000;55:679-83.
10. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
11. Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-91.
12. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
13. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
14. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
16. Mitra AB, Murty VV, Pratap M, et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994;54:637-9.
17. Kihana T, Tsuda H, Teshima S, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994;73:148-53.
18. Wong YF, Chung TK, Cheung TH, et al. HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. J Obstet Gynaecol Res 1996;22:171-5.
19. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-86.
20. Nevin J, Laing D, Kaye P, et al. The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol 1999;73:354-8.
21. Ngan HY, Cheung AN, Liu SS, et al. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001;22:176-83.
22. Nakano T, Oka K, Ishikawa A, et al. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513-20.
23. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
24. Vincent-Salomon A, de la Rochefordiere A, Salmon R, et al. Frequent association of human papillomavirus 16 and 18 DNA with anal squamous cell and basaloid carcinoma. Mod Pathol 1996;9:614-20.
25. Vincent-Salomon A, Carton M, Freneaux P, et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 2000;36:586-91.
26. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003;42:337-47.
27. Hale RJ, Buckley CH, Fox H, et al. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 1992;45:594-6.
28. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002;33:105-10.
29. Rodrigo JP, Ramos S, Lazo PS, et al. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur J Cancer 1996;32A:2004-10.
30. Suo Z, Su W, Holm R, et al. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res 1995;15:2797-8.
31. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31, 1.
32. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79:2162-70.
33. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-8.
34. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-83.
35. Savinainen KJ, Saramaki OR, Linja MJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160:339-45.